通络消癥汤治疗乙肝肝硬化代偿期肝郁脾虚夹瘀证疗效观察
详细信息    查看全文 | 推荐本文 |
  • 英文篇名:Observation of curative effect of Tongluo Xiaozheng decoction on hepatitis B compensated cirrhosis with syndrome of liver-stagnation and spleen-deficiency with blood stasis
  • 作者:周文锋
  • 英文作者:ZHOU Wen-feng;The Fifth People's Hospital of Anyang City in Henan Province;
  • 关键词:乙型肝炎 ; 肝硬化 ; 代偿期 ; 肝郁脾虚夹瘀证 ; 通络消癥汤
  • 英文关键词:hepatitis B;;compensated period;;syndrome of liver-stagnation and spleen-deficiency with blood stasis;;Tongluo Xiaozheng decoction
  • 中文刊名:SHIX
  • 英文刊名:Shanxi Journal of Traditional Chinese Medicine
  • 机构:河南省安阳市第五人民医院;
  • 出版日期:2019-03-15
  • 出版单位:山西中医
  • 年:2019
  • 期:v.35
  • 语种:中文;
  • 页:SHIX201903008
  • 页数:3
  • CN:03
  • ISSN:14-1110/R
  • 分类号:21-22+28
摘要
目的:观察通络消癥汤治疗乙肝肝硬化代偿期肝郁脾虚夹瘀证临床疗效。方法:将136例肝郁脾虚夹瘀证乙肝肝硬化代偿期患者分为两组各68例。治疗组给予通络消癥汤治疗,对照组给予常规西医治疗,对比两组的临床疗效。结果:治疗组患者HA、LN、CIV及PCⅢ水平以及中医症状总积分均明显低于对照组(P﹤0.05);治疗组总有效率为97.06%,明显高于对照组的86.76%(P﹤0.05)。结论:通络消癥汤治疗肝郁脾虚夹瘀证乙肝肝硬化代偿期患者,可改善患者临床症状。
        Objective:To observe the clinical effect of Tongluo Xiaozheng decoction on hepatitis B compensated cirrhosis with syndrome of liver-stagnation and spleen-deficiency with blood stasis. Methods:136 cases of patients with hepatitis B compensated cirrhosis with syndrome of liver-stagnation and spleen-deficiency with blood stasis were randomly divided into two group,68 cases in each group. The treatment group was treated with Tongluo Xiaozheng decoction,while the control group was treated with conventional western medicine. The clinical effects of two groups were compared.Results:After treatment,the levels of HA,LN,CIV and PCIII and the total scores of TCM symptoms of patients in treatment group were significantly lower than those in control group(P<0.05);the total effective rate of treatment group was 97.06%,which was significantly higher than 86.76% of control group(P<0.05). Conclusion:In the treatment of hepatitis B compensated cirrhosis with syndrome of liver-stagnation and spleen-deficiency with blood stasis,Tongluo Xiaozheng decoction can improve the clinical symptoms of patients.
引文
[1]孙晓丽.恩替卡韦对失代偿期乙肝肝硬化的治疗效果探讨[J].中国继续医学教育,2016,8(30):137-138.
    [2]崔振利,赵霞,张慧智.乙肝肝硬化治疗中不同核苷类抗病毒药物的应用比较[J].中外医疗,2016,35(3):149-151.
    [3]王建国.阿德福韦酯结合微生态制剂用于乙肝肝硬化治疗临床分析[J].当代医学,2016,22(1):78-79.
    [4]韩俞,袁雨,刘相波.探讨替比夫定联合阿德福韦酯对活动性乙肝肝硬化长期治疗的效果[J].中国卫生标准管理,2016,7(14):98-99.
    [5]Shen Pan,Xiao-Qi Wang,Qi-yong Guo.Quantitative assessment of hepatic fibrosis in chronic hepatitis B and C:T1 mapping on Gd-EOB-DTPA-enhanced liver magnetic resonance imaging[J].World Journal of Gastroenterology,2018,24(18):2 024-2 035.
    [6]Woo Hee Cho,Hyun Jae Lee,Ki Bae Bang,et al.Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naive chronic hepatitis B:A case report and review of the literature[J].World Journal of Gastroenterology,2018,24(17):1 919-1 924.
    [7]王和木,吴学锋,温梅儿.拉米夫定联合阿德福韦酯对活动性乙肝肝硬化长期治疗的疗效[J].蛇志,2016,28(1):54-55.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700